CAR-T cell therapy for multiple myeloma: An update on the current state and future potential [0.03%]
多发性骨髓瘤的CAR-T细胞疗法：当前状态和未来前景的最新综述
Prateek Pophali,Jacalyn Rosenblatt,David Avigan
Prateek Pophali
The field of multiple myeloma (MM) has seen significant therapeutic advances over the last decade including the recent advent of Chimeric Antigen Receptor T cell (CAR-T) therapy. Currently there are two FDA approved CAR-T products for MM, b...
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use [0.03%]
血液系统恶性肿瘤癌症疫苗的系统性评价：临床应用理性分析及证据
T Anders Olsen,Kevin J Barnum,David Avigan et al.
T Anders Olsen et al.
Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system...
Bin Pan,Robert Peter Gale
Bin Pan
Najing Liu,Yujin Zeng,Ying Wang et al.
Najing Liu et al.
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally. In patients with MM, the number and function of NK cells are suppressed, resulting in reduced immune surveillance and clearance of myeloma cel...
David Kegyes,Bogdan Borlea,Marc Damian et al.
David Kegyes et al.
Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved e...
Diana Cirstea,Benjamin Puliafito,Bridget E Kim et al.
Diana Cirstea et al.
With upfront use of triplet- and quadruplet-based regimens coupled with autologous stem cell transplant (ASCT) and maintenance lenalidomide, a high proportion of multiple myeloma (MM) patients are achieving deep and durable responses. Yet, ...
Corrigendum to "Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)" [Best Pract Res Clin Haematol 38 2 2025] [0.03%]
关于“精准免疫调节：了解和利用细胞因子通路以治疗和预防与免疫相关的不良事件（irAEs）”的勘误修正
Matthew J Hadfield,Ross D Merkin,Sherin J Rouhani et al.
Matthew J Hadfield et al.
Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception [0.03%]
前体浆细胞障碍：分类、风险分层和早期干预的新兴作用
Tarek H Mouhieddine,Irene M Ghobrial,Omar Nadeem
Tarek H Mouhieddine
Precursor plasma cell disorders include monoclonal gammopathy of undermined significance (MGUS) and smoldering multiple myeloma (SMM). These conditions carry a variable risk of progression to symptomatic myeloma and there are ongoing effort...
David Kegyes,Bogdan Borlea,Marc Damian et al.
David Kegyes et al.
Lymphomas are a group of malignant proliferations of B, T or NK-lymphoid cells at different stages of maturation. While they primarily occur in lymph nodes or lymphatic tissues, they can also involve bone marrow, blood, or other organs. Des...
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology [0.03%]
新型细胞(包括间充质干细胞)在血液学治疗中的应用
Leland Metheny
Leland Metheny